The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD), food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS neoplasms.
Name: ONC206
Description: To determine the MTD of single agent oral ONC206
Measure: Maximum Tolerated Dose Time: 28 DaysAllocation: N/A
Single Group Assignment
There is one SNP
Central Nervous System Neoplasms Glioblastoma Gliosarcoma, Adult Anaplastic Oligodendroglioma Anaplastic Astrocytoma Pilocytic Astrocytoma Oligodendroglioma Gliomatosis Cerebri Pleomorphic Xanthoastrocytoma Anaplastic Pleomorphic Xanthoastrocytoma Diffuse Midline Glioma, H3 K27M-Mutant Ependymoma Ependymoma, Anaplastic Medulloblastoma Teratoid Rhabdoid Tumor Neuroectodermal Tumors, Primitive Neuroectodermal Tumors Anaplastic Meningioma Atypical Meningioma Choroid Plexus Neoplasms Pineal Tumor Diffuse Astrocytoma Glial Tumor Neoplasms Glioblastoma Astrocytoma Ependymoma Meningioma Gliosarcoma Oligodendroglioma Medulloblastoma Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Rhabdoid Tumor Nervous System Neoplasms Central Nervous System Neoplasms Neoplasms, Neuroepithelial Choroid Plexus Neoplasms Pinealoma null --- K27M ---